Education
About Us
Working with TipRanks
Follow Us
Insight Molecular Diagnostics (IMDX)
NASDAQ:IMDX
RESEARCH TOOLSreports
IMDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.92 - $4.75
Previous CloseN/A
VolumeN/A
Average Volume (3M)30.79K
Market Cap
$88.15M
Enterprise Value$75.80M
Total Cash (Recent Filing)$24.29M
Total Debt (Recent Filing)$3.37M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Nov 06, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding28,619,750
10 Day Avg. Volume34,063
30 Day Avg. Volume30,790
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue17.81
Enterprise Value/Gross Profit28.07
Enterprise Value/Ebitda-1.22
Forecast
1Y Price Target
$6.13Price Target Upside98.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Product LaunchIMDX's launch of GraftAssureIQ research use only test (RUO) is going well and IMDX continues to sign on transplant centers ahead of its GraftAssureDx Kidney kitted test launch in mid-2026 upon FDA clearance.
Strategic PartnershipsIMDX remains confident in its partnership with BioRad, whereby BioRad and IMDX will comarket GraftAssure inside the US/Germany, and BioRad will take the commercial lead in the ROW.
Bears Say
Financial PositionIMDX ended 2Q25 with ~$24M cash and continues to make progress in managing its cash burn which management expects to remain at ~$6M per quarter until the GraftAssureDx commercial launch.
Insight Molecular Diagnostics News
IMDX FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest stock price was $1.92 and its highest was $4.75 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is $88.15M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is Nov 06, 2025 which is in 50 days.
How were Insight Molecular Diagnostics’s earnings last quarter?
Insight Molecular Diagnostics released its earnings results on Aug 11, 2025. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.23 by -$0.07.
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics does not currently pay dividends.
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate is -0.21.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 28,619,750 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Insight Molecular Diagnostics reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.23. Following the earnings report the stock price went down -3.831%.
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in IMDX
Insight Molecular Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.13 (98.38% Upside)
$6.13 (98.38% Upside)
Hedge Fund Trend
Decreased
By 44.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.32%
12-Months-Change
Fundamentals
Return on Equity
-532.89%
Trailing 12-Months
Asset Growth
-32.39%
Trailing 12-Months
Company Description
Insight Molecular Diagnostics
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
IMDX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a company making solid progress with its FDA submission and assay improvements, supported by strong engagement with transplant centers and a high positive predictive value achievement. However, these positive developments are tempered by challenges in revenue generation and clinical trial enrollment.View all IMDX earnings summariesIMDX Stock 12 Month Forecast
Average Price Target
$6.13
▲(98.38% Upside)
Technical Analysis
Atossa Therapeutics
―
MacroGenics
―
Aziyo Biologics
―
Surrozen
―
Telomir Pharmaceuticals, Inc.
―